RESULTS: The inhibitory capacity of the peptide was evaluated in vitro by plaque assays in order to understand the possible mechanism of action. The results were also confirmed by real-time PCR and Western blot evaluating the expression of viral genes. Hylin-a1 acts to block the herpetic infection interfering at the early stages of both herpes simplex virus type 1 (HSV-1) and type 2 infection. Its mechanism is mainly directed on the membrane, probably by damaging the viral envelope. The same effect was also observed against HSV-1 strains resistant to acyclovir.
CONCLUSIONS: The data presented in this study, such as the increased activity of the peptide when combined to acyclovir, a weak hemolytic profile, an anti-inflammatory effect, and a tolerable half-life in serum, indicates Hylin-a1 as a novel antiherpetic molecule with promising potential in the clinical setting.
结果:为了了解可能的作用机制,通过空斑测定法在体外评估了肽的抑制能力。通过实时PCR和Western印迹评估病毒基因的表达也证实了该结果。Hylin-a1可在1型单纯疱疹病毒(HSV-1)和2型(HSV-2)感染的早期阻止疱疹感染。其机制主要针对膜,可能是通过破坏病毒包膜。对对阿昔洛韦具有抗性的HSV-1菌株也观察到相同的效果。
结论:本研究中提供的数据,例如,当与阿昔洛韦结合时,肽的活性增加,微弱的溶血特征,抗炎作用,在血清中具有可耐受的半衰期,表明Hylin-a1是一种新型的抗疱疹分子,在临床上具有广阔的潜力。